nach oben

CNS Drugs

Erschienen in:

01.06.2007 | Leading Article

Assessing the Role of Drugs in Suicidal Ideation and Suicidality

verfasst von: Dr David M. Reith, Liza Edmonds

Erschienen in: CNS Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

The emergence of suicidal ideation and suicide-related behaviour in patients receiving drug treatment is of concern because of the overall burden of these conditions and the possible link with completed suicide. Observational studies have been useful in generating hypotheses of causality but are confounded by the association between various disease states and increased suicide-related behaviour and completed suicide. The demonstration of causality requires experimental studies, especially randomised controlled trials, and meta-analyses. Unfortunately, the lack of uniform requirements for defining, detecting and recording suicidal ideation, suicide-related behaviour and completed suicide creates difficulties in comparing studies.

Nevertheless, there is evidence of an association between SSRIs and other newer antidepressant drugs and treatment-emergent suicidal ideation and suiciderelated behaviour in both children and adults; however, an increase in completed suicide as a result of treatment with SSRIs and other newer antidepressant drugs has not been demonstrated. Atomoxetine has also been associated with treatmentemergent suicidality, based on the results of a meta-analysis. Although similar associations have been proposed for some antiepileptic drugs, isotretinoin and interferon-α, they are yet to be supported by evidence from randomised controlled trials or meta-analyses.

CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitor antidepressants. London: Committee on the Safety of Medicines, Medicines and Healthcare Products Regulatory Agency, 2004

Hammad T. Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality. Rockville (MD): US Food and Drug Administration, 2004

Committee on the Safety of Medicines. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?.IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON019494&ssTargetNodeId=221 [Accessed 2006 Feb 27]

Duff G. Safety of Seroxat (paroxetine) in children and adolescents under 18 years: contraindication in the treatment of depressive illness. London: Committee on the Safety of Medicines of the Medicines and Healthcare Products Regulatory Agency, 2003

US Food and Drug Administration. FDA statement regarding the anti-depressant Paxil for pediatric population. Rockville (MD): US FDA, 2003 Jun 19

Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330(7488): 396PubMedCrossRef

Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330(7488): 385PubMedCrossRef

Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160(4): 790–2PubMedCrossRef

Ministry of Health. The New Zealand health strategy. Wellington: Ministry of Health, 2000

10.

United States Department of Health and Human Services. The Surgeon General’s call to action to prevent suicide, 1999 [online]. Available from URL: http://www.surgeongeneral.gov/library/calltoaction/calltoaction.pdf [Accessed 2007 Apr 24]

11.

Department of Health. National suicide prevention strategy for England. London: Department of Health, 2002

12.

Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332–9PubMedCrossRef

13.

Wohlfarth TD, van Zwieten BJ, Lekkerkerker F, et al. Antidepressants use in children and adolescents and the risk of suicide. Eur Neuropsychopharmacol 2006; 16(2): 79–83PubMedCrossRef

14.

Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683–96PubMedCrossRef

15.

SmithKline Beecham. A double-blind, multicentre, placebo controlled study of paroxetine in adolescents with unipolar major depression. SmithKline Beecham, 1998 Nov 19. SB document number BRL-029060/RSD-100TNP/2

16.

SmithKline Beecham. Paroxetine BRL-029060: a randomised, multicenter, 8-week, double-blind, placebo-controlled, flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder. Harlow: SmithKline Beecham, 2001

17.

Whittington C, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363(9418): 1341–5PubMedCrossRef

18.

Eli Lilly and Company. Clinical study summary: study B1YMC-HCJW. Fluoxetine versus placebo in the treatment of children and adolescents with obsessive-compulsive disorder. Eli Lilly and Company, 2004

19.

Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1205–15PubMedCrossRef

20.

Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54(11): 1031–7PubMedCrossRef

21.

March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004; 292(7): 807–20PubMedCrossRef

22.

Aursnes I, Tvete IF, Gaasemyr J, et al. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Med 2005; 3: 14PubMedCrossRef

23.

Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995; 5(1): 5–13PubMedCrossRef

24.

Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85(1): 11–28PubMedCrossRef

25.

26.

Katz R. FDA update. Epilepsy Res 2006; 68(1): 85–94PubMedCrossRef

27.

Brent DA, Crumrine PK, Varma R, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. Pediatrics 2000; 85(6): 1086–91

28.

Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80(6): 909–17PubMed

29.

Plioplys S. Depression in children and adolescents with epilepsy. Epilepsy Behav 2003; 4Suppl. 3: S39–45PubMedCrossRef

30.

Jones JE, Hermann BP, Barry JJ, et al. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003; 4Suppl. 3: S31–8PubMedCrossRef

31.

Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999; 53(7): 1503–11PubMedCrossRef

32.

Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4(2): 124–32PubMedCrossRef

33.

MedSafe. Medicines Adverse Reactions Committee 124th meeting: minutes [online]. Available from URL: http://www.medsafe.govt.nz/Profs/adverse/Minutesl24.htm [Accessed 2007 Apr 24]

34.

Marcia L. New agents and second-line therapies for attentiondeficit/ hyperactivity disorder. Pediatr Pharmacother 2002; 8 (4). Epub 2002 Apr

35.

Terrie YC. Pediatric indications for CNS disorders. Pharmacy Times, 2005 Jul: 32

36.

Buitelaar JK, Danckaerts M, Gillberg C, et al. A prospective multicenter, open-label assessment of atomoxetine in North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004; 13(4): 249–57PubMedCrossRef

37.

US Food and Drug Administration, Center for Drug Evaluation and Research. Suicidal thinking in children and adolescents [online]. Available from URL: http://www.fda.gov/medwatch/report/hcp.htm [Accessed 2007 Apr 24]

38.

Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006; 27(1): 1–10PubMedCrossRef

39.

Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55(511): 134–8PubMed

40.

Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45(4): 515–9PubMedCrossRef

41.

Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992; 32(10): 897–904PubMed

42.

Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136(10): 1231–6PubMedCrossRef

43.

Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol 2003; 49(3): 424–32PubMedCrossRef

44.

Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006; 54(3): 420–6PubMedCrossRef

45.

Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26(3): 237–40PubMedCrossRef

46.

Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 731–46PubMedCrossRef

47.

Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med 2000; 160(10): 1522–6PubMedCrossRef

48.

Conner KR, Li Y, Meldrum S, et al. The role of drinking in suicidal ideation: analyses of Project MATCH data. J Stud Alcohol 2003; 64(3): 402–8PubMed

49.

Wilcox HC, Anthony JC. The development of suicide ideation and attempts: an epidemiologic study of first graders followed into young adulthood. Drug Alcohol Depend 2004; 76 Suppl.: S53–67PubMedCrossRef

50.

Cottier LB, Campbell W, Krishna VA, et al. Predictors of high rates of suicidal ideation among drug users. J Nerv Ment Dis 2005; 193(7): 431–7CrossRef

51.

Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97(11): 1383–94PubMedCrossRef

52.

Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288(3): 351–7PubMedCrossRef

53.

Manfredini R, Caracciolo S, Salmi R, et al. The association of low serum cholesterol with depression and suicidal behaviours: new hypothesis for the missing link. J Int Med Res 2000; 28(6): 247–57PubMed

54.

Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomized clinical trials. BMJ 2001; 322(7277): 11–5PubMedCrossRef

55.

Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002; 359: 248–52PubMedCrossRef

56.

Didham RC, McConnell DW, Blair HJ, et al. Suicide and selfharm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005; 60(5): 519–25PubMedCrossRef

57.

Goodwin RD, Marusic A, Hoven CW. Suicide attempts in the United States: the role of physical illness. Soc Sci Med 2003; 56(8): 1783–8PubMedCrossRef

58.

Reza A, Mercy JA, Krug E. Epidemiology of violent deaths in the world. Inj Prev 2001; 7(2): 104–11PubMedCrossRef

59.

Hawton K, Harriss L, Hall S, et al. Deliberate self-harm in Oxford, 1990–2000: a time of change in patient characteristics. Psychol Med 2003; 33(6): 987–95PubMedCrossRef

60.

World Health Organisation. Suicide rates, country reports and charts [online]. Available from URL: http://www.who.int/mental_health/prevention/suicide/country_reports/en/index.html [Accessed 2006 Jun 2]

61.

Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163(1): 41–7PubMedCrossRef

62.

US Food and Drug Administration, Center for Drug Evaluation and Research. Background information on the suicidality classification project [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/classificationProject.htm [Accessed 2006 Mar]

63.

Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA 2005; 293(20): 2487–95PubMedCrossRef

64.

Carter G, Reith DM, Whyte IM, et al. Repeat self-poisoning patients: increasing severity of self-harm is predictive of subsequent suicide. Br J Psychiatry 2005; 186: 253–7PubMedCrossRef

65.

Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm: systematic review. Br J Psychiatry 2002; 181:193–9PubMedCrossRef

66.

Reith DM, Whyte I, Carter G, et al. Risk factors for suicide and other deaths following hospital-treated self poisoning in Australia. Aust N Z J Psychiatry 2004; 38(7): 520–5PubMedCrossRef

67.

Beck AT, Steer RA. Clinical predictors of eventual suicide: a 5-to 10-year prospective study of suicide attempters. J Affect Disord 1989; 17(3): 203–9PubMedCrossRef

68.

Watson D, Goldney R, Fisher L, et al. The measurement of suicidal ideation. Crisis 2001; 22(1): 12–4PubMed

69.

Osman A, Gutierrez PM, Barrios FX, et al. The inventory of suicide orientation-30: further validation with adolescent psychiatric inpatients. J Clin Psychol 2005; 61(4): 481–97PubMedCrossRef

70.

Reynolds WM. Psychometric characteristics of the Adult Suicidal Ideation Questionnaire in college students. J Pers Assess 1991; 56(2): 289–307PubMedCrossRef

71.

Lindenmayer JP, Czobor P, Alphs L, et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res 2003; 63(1–2): 161–70PubMedCrossRef

72.

Hansen L, Kingdon D. Rating suicidality in schizophrenia: items on global scales (HoNOS and CPRS) correlate with a validated suicidality rating scale (InterSePT). Arch Suicide Res 2006; 10(3): 249–52PubMedCrossRef

73.

Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82–91PubMed

74.

Potkin SG, Alphs L, Hsu C, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 2003; 54(4): 444–52PubMedCrossRef

75.

Beck RW, Morris JB, Beck AT. Cross-validation of the suicidal intent scale. Psychol Rep 1974; 34: 445–6PubMedCrossRef

76.

Harriss L, Hawton K. Suicidal intent in deliberate self-harm and the risk of suicide: the predictive power of the Suicide Intent Scale. J Affect Disord 2005; 86(2–3): 225–33PubMedCrossRef

77.

Samuelsson M, Jokinen J, Nordstrom A-L, et al. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatr Scand 2006; 113: 44–7PubMedCrossRef

78.

Haw C, Hawton K, Houston K, et al. Correlates of relative lethality and suicidal intent among deliberate self-harm patients. Suicide Life Threat Behav 2003; 33(4): 353–64PubMedCrossRef

79.

Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63(7): 757–66PubMedCrossRef

80.

Mieczkowski TA, Sweeney JA, Haas GL, et al. Factor composition of the Suicide Intent Scale. Suicide Life Threat Behav 1993; 23(1): 37–45PubMed

81.

Beck AT, Weissman A, Lester D, et al. Classification of suicidal behaviors: II. Dimensions of suicidal intent. Arch Gen Psychiatry 1976; 33(7): 835–7CrossRef

82.

Brown GK, Henriques GR, Sosdjan D, et al. Suicide intent and accurate expectations of lethality: predictors of medical lethality of suicide attempts. J Consult Clin Psychol 2004; 72(6): 1170–4PubMedCrossRef

83.

Henriques G, Wenzel A, Brown GK, et al. Suicide attempters’ reaction to survival as a risk factor for eventual suicide. Am J Psychiatry 2005; 162: 2180–2PubMedCrossRef

Titel: Assessing the Role of Drugs in Suicidal Ideation and Suicidality
verfasst von: Dr David M. Reith
Liza Edmonds
Publikationsdatum: 01.06.2007
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 6/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721060-00003

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Impact of Psychotropic Medications on Simulated Driving

Long-Acting Formulations of Atypical Antipsychotics

Selegiline Transdermal System in Major Depressive Disorder

Oral Disease-Modifying Treatments for Multiple Sclerosis

Effect of HMG-CoA Reductase Inhibitors on β-Amyloid Peptide Levels